Skip to main content
. 2021 Jul 15;106(11):3239–3247. doi: 10.1210/clinem/dgab522

Table 2.

Mean continuous glucose monitoring, glucose management indicator, and percentage of time spent in glucose ranges greater than 250 mg/dL, 181 to 250 mg/dL, 70 to 180 mg/dL, less than 70 mg/dL, and less than 54 mg/dL across all time points

Baseline 1 mo 3 mo 6 mo 9 mo 12 mo P a
n = 52 n = 55 n = 67 n = 70 n = 68 n = 67
Mean glucose, mg/dL 176 ± 39 147 ± 28 147 ± 29 162 ± 35 161 ± 33 168 ± 34 < .001
GMI, % 7.5 ± 0.9 6.8 ± 0.7 6.8 ± 0.7 7.2 ± 0.8 7.2 ± 0.8 7.3 ± 0.8 < .001
CGM glucose range, mg/dL, %
> 250 15.1 ± 17.1 6.7 ± 10.7 7.2 ± 9.8 11.5 ± 13.2 10.9 ± 12.3 13.0 ± 13.6 < .001
181-250 26.4 ± 10.9 16.3 ± 8.6 16.0 ± 9.7 21.1 ± 10.8 21.5 ± 10.7 23.6 ± 9.7 < .001
70-180 57.2 ± 22.5 74.6 ± 16.7 74.6 ± 17.7 65.5 ± 21.2 65.5 ± 20.1 61.3 ± 20.3 < .001
< 70 b 1.2 ± 2.1 2.4 ± 2.4 2.3 ± 2.2 1.9 ± 2.4 2.1 ± 2.1 2.1 ± 2.7 .47
< 54 c 0.2 ± 0.5 0.4 ± 0.5 0.3 ± 0.3 0.3 ± 0.6 0.3 ± 0.4 0.3 ± 0.6 .83

All data reported as mean ± SD.

Abbreviations: CGM, continuous glucose monitoring; GMI, glucose management indicator; IQRs, interquartile ranges.

a P value represents slope from 1 month post diagnosis to 12 months post diagnosis for each category.

b Median (IQRs) for less than 70 mg/dL were 0.3 (0.0-1.6), 1.8 (0.7-3.2), 1.9 (0.8-3.0), 1.2 (0.4-2.5), 1.4 (0.7-3.2), and 1.4 (0.6-2.5) from baseline through 12 months post diagnosis, respectively.

c Median (IQRs) for less than 54 mg/dL were 0.0 (0.0-0.2), 0.2 (0.0-0.5), 0.2 (0.0-0.3), 0.1 (0.0-0.2), 0.2 (0.0-0.4), and 0.1 (0.1-0.3) from baseline through 12 months post diagnosis, respectively.